Mouse homologue of a novel human oncofetal antigen, glypican-3, evokes T-cell-mediated tumor rejection without autoimmune reactions in mice

Clinical Cancer Research

Volumn 10, Issue 24, 2004, Pages 8630-8640

  Nakatsura, Tetsuya ^a   Komori, Hiroyuki ^a   Kubo, Tatsuko ^a   Yoshitake, Yoshihiro ^a   Senju, Satoru ^a   Katagiri, Toyomasa ^b   Furukawa, Yoichi ^b   Ogawa, Michio ^a   Nakamura, Yusuke ^b   Nishimura, Yasuharu ^a  

^a KUMAMOTO UNIVERSITY   (Japan)

^b UNIVERSITY OF TOKYO   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

CD8 ANTIGEN; COMPLEMENTARY DNA; GLYPICAN 3; ONCOFETAL ANTIGEN; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL MODEL; ARTICLE; BONE MARROW CELL; CANCER CELL CULTURE; CANCER GROWTH; CANCER IMMUNOTHERAPY; CANCER INHIBITION; COLON CANCER; DENDRITIC CELL; DNA MICROARRAY; FEMALE; GENE; GPC3 GENE; HISTOLOGY; IMMUNOGENICITY; IMMUNOHISTOCHEMISTRY; LIVER CELL CARCINOMA; LYMPHOCYTE DEPLETION; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; T LYMPHOCYTE;

ADENOCARCINOMA; ANIMALS; ANTIGENS, NEOPLASM; AUTOIMMUNITY; CD8-POSITIVE T-LYMPHOCYTES; COLORECTAL NEOPLASMS; DENDRITIC CELLS; GLYPICANS; HUMANS; MEMBRANE PROTEINS; MICE; MICE, INBRED BALB C; NEOPLASM PROTEINS; PEPTIDE FRAGMENTS; SPLEEN; T-LYMPHOCYTES, CYTOTOXIC; TUMOR MARKERS, BIOLOGICAL;

EID: 19944428703     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-04-1177     Document Type: Article

References (49)

1. Schafer DF, Sorrell MF. Hepatocellular carcinoma. Lancet 1999;353:1253-7.
2. van der Bruggen P, Traversari C, Chomez P, et al. A gene encoding an antigen recognized by cytolytic T lymphocytes on a human melanoma. Science (Wash. DC) 1991;254:1643-7.
3. Rosenberg SA. Progress in human tumour immunology and immunotherapy. Nature (Lond.) 2001;411:380-4.
4. Morgan RA, Dudley ME, Yu YY, et al. High efficiency TCR gene transfer into primary human lymphocytes affords avid recognition of melanoma tumor antigen glycoprotein 100 and does not alter the recognition of autologous melanoma antigens. J Immunol 2003;171:3287-95.
5. Maeda Y, Ito M, Harashima N, et al. Cleavage and polyadenylation specificity factor (CPSF)-derived peptides can induce HLA-A2-restricted and tumor-specific CTLs in the majority of gastrointestinal cancer patients. Int J Cancer 2002;99:409-17.
6. Azuma K, Shichijo S, Maeda Y, et al. Mutated p53 gene encodes a nonmutated epitope recognized by HLA-B*4601-restricted and tumor cell-reactive CTLs at tumor site. Cancer Res 2003;63:854-8.
7. Park S, Lim Y, Lee D, et al. Identification and characterization of a novel cancer/testis antigen gene CAGE-1. Biochim Biophys Acta 2003;1625:173-82.
8. Jager E, Chen YT, Drijfhout JW. et al. Simultaneous humoral and cellular immune response against cancer-testis antigen NY-ESO-1: definition of human histocompatibility leukocyte antigen (HLA)-A2-binding peptide epitopes. J Exp Med 1998;187:265-70.
9. Nakatsura T, Senju S, Yamada K, Jotsuka T, Ogawa M, Nishimura Y. Gene cloning of immunogenic antigens overexpressed in pancreatic cancer. Biochem Biophys Res Commun 2001;281:936-44.
10. Nakatsura T, Senju S, Ito M, Nishimura Y, Itoh K. Cellular and humoral immune responses to a human pancreatic cancer antigen, coactosin-like protein, originally defined by the SEREX method. Eur J Immunol 2002;32:826-36.
11. Monji M, Senju S, Nakatsura T, et al. Head and neck cancer antigens recognized by the humoral immune system. Biochem Biophys Res Commun 2002;294:734-41.
12. Hasegawa S, Furukawa Y, Li M, et al. Genome-wide analysis of gene expression in intestinal-type gastric cancers using a complementary DNA microarray representing 23,040 genes. Cancer Res 2002;62:7012-7.
13. Zembutsu H, Ohnishi Y, Tsunoda T, et al. Genome-wide cDNA microarray screening to correlate gene expression profiles with sensitivity of 85 human cancer xenografts to anticancer drugs. Cancer Res 2002;62:518-27.
14. Kitahara O, Furukawa Y, Tanaka T, et al. Alterations of gene expression during colorectal carcinogenesis revealed by cDNA microarrays after laser-capture microdissection of tumor tissues and normal epithelia. Cancer Res 2001;61:3544-9.
15. Yu Y, Khan J, Khanna C, Helman L, Meltzer PS, Merlino G. Expression profiling identifies the cytoskeletal organizer ezrin and the developmental homeoprotein Six-1 as key metastatic regulators. Nat Med 2004;10:175-81.
16. Kitahara O, Katagiri T, Tsunoda T, Harima Y, Nakamura Y. Classification of sensitivity or resistance of cervical cancers to ionizing radiation according to expression profiles of 62 genes selected by cDNA microarray analysis. Neoplasia 2002;4:295-303.
17. Yoshitake Y, Nakatsura T, Monji M, et al. Proliferation potential-related protein, an ideal esophageal cancer antigen for immunotherapy, identified using cDNA microarray analysis. Clin Cancer Res 2004;10:6437-48.
18. Okabe H, Satoh S, Kato T, et al. Genome-wide analysis of gene expression in human hepatocellular carcinomas using cDNA microarray: identification of genes involved in viral carcinogenesis and tumor progression. Cancer Res 2001;61:2129-37.
19. Saito-Hisaminato A, Katagiri T, Kakiuchi S, Nakamura T, Tsunoda T, Nakamura Y. Genome-wide profiling of gene expression in 29 normal human tissues with a cDNA microarray. DNA Res 2002;9:35-45.
20. Nakatsura T, Yoshitake Y, Senju S, et al. Glypican-3, overexpressed specifically in human hepatocellular carcinoma, is a novel tumor marker. Biochem Biophys Res Commun 2003;306:16-25.
21. Nakatsura T, Kageshita T, Ito S, et al. Identification of glypican-3 as a novel tumor marker for melanoma. Clin Cancer Res 2004;10:6612-21.
22. Hattori K, Matsushita R, Kimura K, Abe Y, Nakashima E. Synergistic effect of indomethacin with Adriamycin and cisplatin on tumor growth. Biol Pharm Bull 2001;24:1214-7.
23. Kai M, Nakatsura T, Egami H, Senju S, Nishimura Y, Ogawa M. Heat shock protein 105 is overexpressed in a variety of human tumors. Oncol Rep 2003;10:1777-82.
24. Hirota T, Morisaki T, Nishiyama Y, et al. Zyxin, a regulator of actin filament assembly, targets the mitotic apparatus by interacting with h-warts/LATS1 tumor suppressor. J Cell Biol 2000;149:1073-86.
25. Matsuyoshi H, Senju S, Hirata S, Yoshitake Y, Uemura Y, Nishimura Y. Enhanced priming of antigen-specific CTLs in vivo by embryonic stem cell-derived dendritic cells expressing chemokine along with antigenic protein: application to antitumor vaccination. J Immunol 2004;172:776-86.
26. Hsu HC, Cheng W, Lai PL. Cloning and expression of a developmentally regulated transcript MXR7 in hepatocellular carcinoma: biological significance and temporospatial distribution. Cancer Res 1997;57:5179-84.
27. Zhu ZW, Friess H, Wang L, et al. Enhanced glypican-3 expression differentiates the majority of hepatocellular carcinomas from benign hepatic disorders. Gut 2001;48:558-64.
28. Sung YK, Hwang SY, Park MK, et al. Glypican-3 is overexpressed in human hepatocellular carcinoma. Cancer Sci 2003;94:259-62.
29. Midorikawa Y, Ishikawa S, Iwanari H, et al. Glypican-3, overexpressed in hepatocellular carcinoma, modulates FGF2 and BMP-7 signaling. Int J Cancer 2003;103:455-65.
30. Capurro M, Wanless IR, Sherman M, et al. Glypican-3: a novel serum and histochemical marker for hepatocellular carcinoma. Gastroenterology 2003;125:89-97.
31. Hippo Y, Watanabe K, Watanabe A, et al. Identification of soluble NH2-terminal fragment of glypican-3 as a serological marker for early-stage hepatocellular carcinoma. Cancer Res 2004;64:2418-23.
32. Dummer W, Niethammer AG, Baccala R, et al. T cell homeostatic proliferation elicits effective antitumor autoimmunity. J Clin Investig 2002;110:185-92.
33. Maine GN, Mule JJ. Making room for T cells. J Clin Investig 2002;110:157-9.
34. Dudley ME, Wunderlich JR, Robbins PF, et al. Cancer regression and autoimmunity in patients after clonal repopulation with antitumor lymphocytes. Science (Wash. DC) 2002;298:850-4.
35. Pilia G, Hughes-Benzie RM, MacKenzie A, et al. Mutations in GPC3, a glypican gene, cause the Simpson-Golabi-Behmel overgrowth syndrome. Nat Genet 1996;12:241-7.
36. Neri G, Gurrieri F, Zanni G, Lin A. Clinical and molecular aspects of the Simpson-Golabi-Behmel syndrome. Am J Med Genet 1998;79:279-83.
37. Cano-Gauci DF, Song HH, Yang H, et al. Glypican-3-deficient mice exhibit developmental overgrowth and some of the abnormalities typical of Simpson-Golabi-Behmel syndrome. J Cell Biol 1999;146:255-64.
38. Lin H, Huber R, Schlessinger D, Morin PJ. Frequent silencing of the GPC3 gene in ovarian cancer cell lines. Cancer Res 1999;59:807-10.
39. Rivoltini L, Kawakami Y, Sakaguchi K, et al. Induction of tumor-reactive CTL from peripheral blood and tumor-infiltrating lymphocytes of melanoma patients by in vitro stimulation with an immunodominant peptide of the human melanoma antigen MART-1. J Immunol 1995;154:2257-65.
40. Bakker AB, Schreurs MW, de Boer AJ, et al. Melanocyte lineage-specific antigen gp100 is recognized by melanoma-derived tumor-infiltrating lymphocytes. J Exp Med 1994;179:1005-9.
41. Kawakami Y, Eliyahu S, Jennings C, et al. Recognition of multiple epitopes in the human melanoma antigen gp100 by tumor-infiltrating T lymphocytes associated with in vivo tumor regression. J Immunol 1995;154:3961-8.
42. Brichard V, Van Pel A, Wolfel T, et al. The tyrosinase gene codes for an antigen recognized by autologous cytolytic T lymphocytes on HLA-A2 melanomas. J Exp Med 1993;178:489-95.
43. Jungbluth AA, Chen YT, Stockert E, et al. Immunohistochemical analysis of NY-ESO-1 antigen expression in normal and malignant human tissues. Int J Cancer 2001;92:856-60.
44. Neumann E, Engelsberg A, Decker J, et al. Heterogeneous expression of the tumor-associated antigens RAGE-1, PRAME, and glycoprotein 75 in human renal cell carcinoma: candidates for T-cell-based immunotherapies? Cancer Res 1998;58:4090-5.
45. Date Y, Kimura A, Kato H, Sasazuki T. DNA typing of the HLA-A gene: population study and identification of four new alleles in Japanese. Tissue Antigens 1996;47:93-101.
46. Ohmori M, Yasunaga S, Maehara Y, Sugimachi K, Sasazuki T. DNA typing of HLA class I (HLA-A) and class II genes (HLA-DR, -DQ and -DP) in Japanese patients with gastric cancer. Tissue Antigens 1997;50:277-82.
47. Falk K, Rotzschke O, Stevanovic S, Jung G, Rammensee HG. Allele-specific motifs revealed by sequencing of self-peptides eluted from MHC molecules. Nature (Lond.) 1991;351:290-6.
48. Maier R, Falk K, Rotzschke O, et al. Peptide motifs of HLA-A3, -A24, and -B7 molecules as determined by pool sequencing. Immunogenetics 1994;40:306-8.
49. Okugawa T, Ikuta Y, Takahashi Y, et al. A novel human HER2-derived peptide homologous to the mouse K(d)-restricted tumor rejection antigen can induce HLA-A24-restricted cytotoxic T lymphocytes in ovarian cancer patients and healthy individuals. Eur J Immunol 2000;30:3338-46.